Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06440850
Title	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	City of Hope Medical Center
Indications	follicular thyroid carcinoma papillary thyroid carcinoma oncocytic carcinoma of the thyroid
Therapies	Cobimetinib + Vemurafenib
Age Groups:	adult \| senior
Covered Countries	USA